Clinical Trials for COVID‐19: Can we Better Use the Short Window of Opportunity?

The scientific community has risen to the coronavirus disease 2019 (COVID‐19) challenge, coming up with an impressive list of candidate drugs and vaccines targeting an array of pharmacological and immunological mechanisms. Yet, generating clinical evidence of efficacy and safety of these candidate t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2020-10, Vol.108 (4), p.730-733
Main Authors: Eichler, Hans‐Georg, Cavaleri, Marco, Enzmann, Harald, Scotti, Francesca, Sepodes, Bruno, Sweeney, Fergus, Vamvakas, Spiros, Rasi, Guido
Format: Article
Language:English
Subjects:
Academic Medical Centers - methods
Academic Medical Centers - trends
Betacoronavirus
Biomedical Research - methods
Biomedical Research - trends
Clinical Trials as Topic - methods
Coronavirus Infections - epidemiology
Coronavirus Infections - therapy
COVID-19
Drug and Narcotic Control - trends
Drug Industry - methods
Drug Industry - trends
Humans
Pandemics
Pneumonia, Viral - epidemiology
Pneumonia, Viral - therapy
Review
Reviews
SARS-CoV-2
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The scientific community has risen to the coronavirus disease 2019 (COVID‐19) challenge, coming up with an impressive list of candidate drugs and vaccines targeting an array of pharmacological and immunological mechanisms. Yet, generating clinical evidence of efficacy and safety of these candidate treatments may be frustrated by the absence of comprehensive trial coordination mechanisms. Many small stand‐alone trials and observational studies of single‐agent interventions are currently running or in planning; many of these will likely not deliver robust results that could support regulatory and patient‐level treatment decisions. In this paper, we discuss actions that all stakeholders in the clinical trial ecosystem need to take to ensure that the window of opportunity during this pandemic will not shut, both for patients in need of treatment and for researchers to conduct decision‐relevant clinical trials.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.1891